IL291076A - Dimeric antigen receptors (dar) that bind bcma - Google Patents

Dimeric antigen receptors (dar) that bind bcma

Info

Publication number
IL291076A
IL291076A IL291076A IL29107622A IL291076A IL 291076 A IL291076 A IL 291076A IL 291076 A IL291076 A IL 291076A IL 29107622 A IL29107622 A IL 29107622A IL 291076 A IL291076 A IL 291076A
Authority
IL
Israel
Prior art keywords
dar
antigen receptors
dimeric antigen
bind bcma
bcma
Prior art date
Application number
IL291076A
Other languages
English (en)
Hebrew (he)
Inventor
Henry Hongjun Ji
Wenzhong Guo
Yanliang Zhang
Bei Bei Ding
Gunnar F Kaufmann
Original Assignee
Sorrento Therapeutics Inc
Henry Hongjun Ji
Wenzhong Guo
Yanliang Zhang
Bei Bei Ding
Gunnar F Kaufmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc, Henry Hongjun Ji, Wenzhong Guo, Yanliang Zhang, Bei Bei Ding, Gunnar F Kaufmann filed Critical Sorrento Therapeutics Inc
Publication of IL291076A publication Critical patent/IL291076A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL291076A 2019-09-05 2022-03-02 Dimeric antigen receptors (dar) that bind bcma IL291076A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962896190P 2019-09-05 2019-09-05
US201962896990P 2019-09-06 2019-09-06
US201962910341P 2019-10-03 2019-10-03
US201962943069P 2019-12-03 2019-12-03
US202063030145P 2020-05-26 2020-05-26
PCT/US2020/049538 WO2021046445A1 (en) 2019-09-05 2020-09-04 Dimeric antigen receptors (dar) that bind bcma

Publications (1)

Publication Number Publication Date
IL291076A true IL291076A (en) 2022-05-01

Family

ID=74852154

Family Applications (1)

Application Number Title Priority Date Filing Date
IL291076A IL291076A (en) 2019-09-05 2022-03-02 Dimeric antigen receptors (dar) that bind bcma

Country Status (10)

Country Link
US (1) US20220251168A1 (enExample)
EP (1) EP4025227A4 (enExample)
JP (1) JP2022546577A (enExample)
KR (1) KR20220057598A (enExample)
CN (1) CN114650829A (enExample)
AU (1) AU2020341712A1 (enExample)
CA (1) CA3149867A1 (enExample)
IL (1) IL291076A (enExample)
MX (1) MX2022002723A (enExample)
WO (1) WO2021046445A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210133261A (ko) * 2019-02-26 2021-11-05 소렌토 쎄라퓨틱스, 인코포레이티드 Bcma에 결합하는 항원 결합 단백질
EP4139345A1 (en) 2020-04-24 2023-03-01 Sorrento Therapeutics, Inc. Memory dimeric antigen receptors
EP4326292A4 (en) * 2021-04-23 2025-03-26 Vivasor, Inc. Dimeric antigen receptors (dars) that bind gd2
IL311141A (en) * 2021-09-06 2024-04-01 Genmab As Antibodies capable of binding to CD27, their variants and uses thereof
CN117986387A (zh) * 2023-05-31 2024-05-07 四川大学华西医院 一种新型小型化car设计及制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170051037A1 (en) * 2014-05-02 2017-02-23 Cellectis Cs1 specific multi-chain chimeric antigen receptor
EP3842448A1 (en) * 2015-05-15 2021-06-30 City of Hope Chimeric antigen receptor compositions
US11173179B2 (en) * 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
MX2018004721A (es) * 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
AU2018290272A1 (en) * 2017-06-21 2020-01-30 Gsbio, Llc Heterodimeric bispecific antibodies
SG11202003501XA (en) * 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
AU2019231315A1 (en) * 2018-03-09 2020-09-17 Vivasor, Inc. Dimeric antigen receptors (DAR)
KR20210133261A (ko) * 2019-02-26 2021-11-05 소렌토 쎄라퓨틱스, 인코포레이티드 Bcma에 결합하는 항원 결합 단백질

Also Published As

Publication number Publication date
KR20220057598A (ko) 2022-05-09
AU2020341712A1 (en) 2022-03-31
EP4025227A4 (en) 2023-11-01
JP2022546577A (ja) 2022-11-04
EP4025227A1 (en) 2022-07-13
CA3149867A1 (en) 2021-03-11
CN114650829A (zh) 2022-06-21
WO2021046445A1 (en) 2021-03-11
MX2022002723A (es) 2022-03-22
US20220251168A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
IL277181A (en) dimer antigen receptors (DAR)
IL291076A (en) Dimeric antigen receptors (dar) that bind bcma
IL325502A (en) BCMA chimeric antigen receptors and their uses
SG11202003866QA (en) Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
ZA201906358B (en) Improved antigen binding receptors
IL278853A (en) Antiproliferative compounds and a bispecific antibody against BCMA and CD3 for combined use
IL285909A (en) Anti-bcma chimeric antigen receptors
IL257233B (en) Monoclonal antibodies against bcma
IL252783A0 (en) bcma chimeric antigen receptors
EP3131927B8 (en) Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
ZA202005837B (en) Cd83-binding chimeric antigen receptors
IL248006A0 (en) Antibodies that bind to the human cannabinoid 1 receptor
AU2021330958A9 (en) Bcma chimeric antigen receptors
IL285813A (en) antigenic proteins that bind bmca
IL318416A (en) Chimeric antigen receptors specific for GPRC5D and BCMA
ZA201802807B (en) Antibodies that bind human cannabinoid 1 (cb1) receptor
IL281958A (en) Pharmaceutical preparations containing bispecific anti-CD37 antibodies
HK40068352A (en) Dimeric antigen receptors (dar) that bind bcma
HK40041209A (en) Dimeric antigen receptors (dar)
HK40096224A (en) Bcma chimeric antigen receptors
GB201908239D0 (en) Chimeric antigen receptors
IL286162A (en) Pharmaceutical preparations containing anti-lingo-1 antibodies
HK40043655A (en) Bcma chimeric antigen receptors and uses thereof
GB202004404D0 (en) Chimeric antigen receptors
GB202001261D0 (en) Chimeric antigen receptors